[{"address1": "230 Park Avenue", "address2": "Suite 3350", "city": "New York", "state": "NY", "zip": "10169", "country": "United States", "phone": "646 885 8505", "website": "https://www.ymabs.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.", "fullTimeEmployees": 100, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael  Rossi", "age": 53, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 481205, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas  Gad", "age": 54, "title": "Founder, Chief Business Officer & Vice Chairman", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1111627, "exercisedValue": 0, "unexercisedValue": 901500}, {"maxAge": 1, "name": "Mr. Peter P. Pfreundschuh CPA", "age": 55, "title": "CFO & Treasurer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joris Wiel Jan Wilms", "age": 50, "title": "Senior VP & COO", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Torben  Lund-Hansen M.Sc., Ph.D.", "age": 73, "title": "Senior VP & CTO", "yearBorn": 1951, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Courtney  Dugan", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vignesh  Rajah M.B.A., MBBS", "age": 59, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 406275, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Norman D.  LaFrance FACNP, FACP, M.D.", "age": 76, "title": "Chief Development Officer", "yearBorn": 1948, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Doug  Gentilcore", "title": "Senior VP & Head of DANYELZA Business Unit", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.28, "open": 6.27, "dayLow": 6.095, "dayHigh": 6.49, "regularMarketPreviousClose": 6.28, "regularMarketOpen": 6.27, "regularMarketDayLow": 6.095, "regularMarketDayHigh": 6.49, "beta": 0.671, "forwardPE": -13.333333, "volume": 750949, "regularMarketVolume": 750949, "averageVolume": 344168, "averageVolume10days": 519320, "averageDailyVolume10Day": 519320, "bid": 6.21, "ask": 6.26, "bidSize": 200, "askSize": 200, "marketCap": 279931872, "fiftyTwoWeekLow": 6.01, "fiftyTwoWeekHigh": 20.9, "priceToSalesTrailing12Months": 3.3107266, "fiftyDayAverage": 9.2066, "twoHundredDayAverage": 12.27375, "currency": "USD", "enterpriseValue": 212884720, "profitMargins": -0.28224, "floatShares": 27290432, "sharesOutstanding": 44789100, "sharesShort": 3564526, "sharesShortPriorMonth": 3838903, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.0796, "heldPercentInsiders": 0.12207, "heldPercentInstitutions": 0.72169995, "shortRatio": 9.85, "shortPercentOfFloat": 0.0955, "impliedSharesOutstanding": 44934500, "bookValue": 2.065, "priceToBook": 3.0266342, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -23864000, "trailingEps": -0.54, "forwardEps": -0.58, "enterpriseToRevenue": 2.518, "enterpriseToEbitda": -9.116, "52WeekChange": -0.48389763, "SandP52WeekChange": 0.23809385, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "YMAB", "underlyingSymbol": "YMAB", "shortName": "Y-mAbs Therapeutics, Inc.", "longName": "Y-mAbs Therapeutics, Inc.", "firstTradeDateEpochUtc": 1537536600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ef4c7aed-ff51-3117-8a16-0b2c87e3c948", "messageBoardId": "finmb_378585331", "gmtOffSetMilliseconds": -18000000, "currentPrice": 6.25, "targetHighPrice": 26.0, "targetLowPrice": 11.0, "targetMeanPrice": 20.36364, "targetMedianPrice": 22.0, "recommendationMean": 1.72727, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 68122000, "totalCashPerShare": 1.521, "ebitda": -23352000, "totalDebt": 1075000, "quickRatio": 3.481, "currentRatio": 3.917, "totalRevenue": 84553000, "debtToEquity": 1.163, "revenuePerShare": 1.921, "returnOnAssets": -0.11983, "returnOnEquity": -0.24784, "grossProfits": 75105000, "freeCashflow": 1186750, "operatingCashflow": -21880000, "revenueGrowth": -0.097, "grossMargins": 0.88825995, "ebitdaMargins": -0.27618, "operatingMargins": -0.42521998, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-25"}]